<div id="readability-page-1"><p>Invesco Ltd. trimmed its position in shares of  Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 33.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 571,549 shares of the company's stock after selling 285,452 shares during the period. Invesco Ltd. owned about 1.15% of Axsome Therapeutics worth $59,664,000 at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>Axsome Therapeutics</strong> alerts:</span></p></div><ul><li>5 medical stocks growing earnings by triple digits</li></ul><p>Other institutional investors also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd purchased a new stake in shares of  Axsome Therapeutics in the 1st quarter valued at approximately $25,000.  Quantbot Technologies LP purchased a new position in  Axsome Therapeutics in the first quarter valued at $31,000.  AlphaQuest LLC acquired a new stake in  Axsome Therapeutics in the first quarter valued at $38,000.  BI Asset Management Fondsmaeglerselskab A S purchased a new stake in  Axsome Therapeutics during the 1st quarter worth about $47,000.  Finally, Ameritas Advisory Services LLC purchased a new stake in  Axsome Therapeutics during the 2nd quarter worth about $77,000. Hedge funds and other institutional investors own  81.49% of the company's stock. </p><h2>Analyst Ratings Changes</h2><p>AXSM has been the topic of several research analyst reports. Morgan Stanley raised their target price on Axsome Therapeutics from $194.00 to $196.00 and gave the stock an &#34;overweight&#34; rating in a research report on Tuesday, November 4th. Guggenheim increased their price target on shares of Axsome Therapeutics from $200.00 to $205.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, November 4th. Royal Bank Of Canada boosted their price objective on shares of Axsome Therapeutics from $189.00 to $198.00 and gave the stock an &#34;outperform&#34; rating in a research report on Tuesday, November 4th. Mizuho upped their target price on shares of Axsome Therapeutics from $200.00 to $202.00 and gave the company an &#34;outperform&#34; rating in a report on Thursday, November 6th. Finally, Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Axsome Therapeutics in a research note on Wednesday, October 8th. One research analyst  has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one  has issued  a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $179.88.</p><ul><li>Struggling Axsome Stock Could Bounce Back on Drug Trial Success</li></ul><p><b>View Our Latest Stock Analysis on AXSM</b></p><h2>Insider Activity at Axsome Therapeutics</h2><p>In other Axsome Therapeutics news, COO Mark L. Jacobson sold 10,000 shares of the company's stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $115.96, for a total transaction of $1,159,600.00. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, CEO Herriot Tabuteau sold 10,558 shares of the firm's stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $148.18, for a total transaction of $1,564,484.44. Following the completion of the sale, the chief executive officer owned 7,229 shares of the company's stock, valued at $1,071,193.22. This trade represents a 59.36% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 407,959 shares of company stock valued at $52,645,040 in the last 90 days. Company insiders own  22.30% of the company's stock. </p><h2>Axsome Therapeutics Price Performance</h2><ul><li>Why this is an Awesome Time to Buy Axsome Therapeutics</li></ul><p>Shares of AXSM opened at $149.26 on Thursday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.50 and a current ratio of 1.57. Axsome Therapeutics, Inc. has a fifty-two week low of $75.56 and a fifty-two week high of $152.94. The firm has a 50-day simple moving average of $136.66 and a 200-day simple moving average of $119.76. The company has a market capitalization of $7.52 billion, a price-to-earnings ratio of -31.96 and a beta of 0.48. </p><p>Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.12). Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The company had revenue of $170.99 million for the quarter, compared to analysts' expectations of $162.96 million. The firm's revenue was up 63.2% on a year-over-year basis.  On average, equities research analysts anticipate that  Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year. </p><h2>About Axsome Therapeutics</h2> (Free Report)<p>Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Axsome Therapeutics</li><li>Dividend King Proctor &amp; Gamble Is A Buy On Post-Earnings Weakness </li><li>Market Momentum: 3 Stocks Poised for Major Breakouts</li><li>Growth Investing: Should You Adopt This Investing Strategy in 2022?</li><li>3 Reasons Casey’s General Stores Will Continue Trending Higher</li><li>Roth IRA Calculator: Calculate Your Potential Returns</li><li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Axsome Therapeutics Right Now?</h2><p>Before you consider Axsome Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.</p><p>While Axsome Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AXSM

<p>Invesco Ltd. reduced its stake in Axsome Therapeutics, Inc. by 33.3% in Q2, selling 285,452 shares and retaining 571,549 shares worth $59.66 million. Other institutional investors also adjusted their positions. Analysts have mixed ratings on AXSM, with a consensus of 'Moderate Buy' and an average price target of $179.88. Insiders sold significant shares recently. Axsome's stock opened at $149.26, with a market cap of $7.52 billion. The company reported Q3 revenue of $170.99 million, up 63.2% YoY, but missed EPS estimates.</p>

Invesco Ltd. Decreases Stake in Axsome Therapeutics, Inc. $AXSM